Nevertheless, NfL is useful as a differentiating biomarker as elevations are greater in frontotemporal dementia and amyotrophic lateral sclerosis compared to atypical parkinsonism and various dementias especially when aged-related concentration cut-offs are considered.84 Overall, NfL is so far the most established biomarker in frontotemporal dementia and amyotrophic lateral sclerosis, although its utility across the spectrum of neurodegenerative diseases indicates that more specific biomarkers are required. The gene discussed is NEFL; the disease is neurodegenerative disease.